All In Biotech

NDA 209191 · Hospira

Bortezomib

Bortezomib · Intravenous, Subcutaneous · Proteasome Inhibitor

Last checked: Nov 20, 2026Latest source record: Dec 9, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

May 2, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,027

156 Phase 3, 82 recruiting

FAERS reports

33,996

32,180 serious, 6,006 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 27, 2023.

Bortezomib for Injection is a proteasome inhibitor indicated for: • Treatment of adult patients with multiple myeloma. ( 1.1 ) • Treatment of adult patients with mantle cell lymphoma. ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for Injection is indicated for the treatment of adult patients with mantle cell lymphoma.

Mechanism: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 9, 2022 Supplement 3 · Efficacy LabelLetter
  • May 2, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
2 products under this application
  • BORTEZOMIB · BORTEZOMIB 1MG/VIAL · POWDER, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
  • BORTEZOMIB · BORTEZOMIB 2.5MG/VIAL · POWDER, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Bortezomib" as an intervention, any sponsor and status, largest first.

All 1,027 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • plasma cell myeloma5,249
  • off label use3,253
  • drug ineffective2,307
  • neuropathy peripheral1,904
  • thrombocytopenia1,807
  • death1,591
  • pneumonia1,575
  • neutropenia1,428
  • diarrhoea1,414
  • fatigue1,162
  • anaemia1,136
  • disease progression1,072

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200415
200525
200617
200737
200878
2009161
2010248
2011313
2012409
2013556
2014800
20151,311
20161,077
20171,232
20181,699
20192,521
20203,037
20213,110
20223,923
20233,918
20243,760
20253,243
20262,506

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bortezomib* (Bortezomib)

2024 spending

$3.1M

Beneficiaries

719

4,286 claims

Per beneficiary

$4,318

$261.26 per unit

View as table
YearSpending
2020$2,261,525
2021$3,209,334
2022$4,278,056
2023$3,999,340
2024$3,104,837

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,307 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.